OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 04:51 UTC. Every row links to its source record.

BRIP1 BRCA1 interacting DNA helicase 1

ENSG00000136492 · protein coding · Open Targets profile

DNA-dependent ATPase and 5'-3' DNA helicase required for the maintenance of chromosomal stability (PubMed:11301010, PubMed:14983014, PubMed:16116421, PubMed:16153896, PubMed:17596542, PubMed:36608669). Acts late in the Fanconi anemia pathway, after FANCD2 ubiquitination (PubMed:14983014, PubMed:16153896). Involved in the repair of DNA double-strand breaks by homologous recombination in a manner that depends on its association with BRCA1 (PubMed:14983014, PubMed:16153896). Involved in the repair of abasic sites at replication forks by promoting the degradation of DNA-protein cross-links: acts by catalyzing unfolding of HMCES DNA-protein cross-link via its helicase activity, exposing the underlying DNA and enabling cleavage of the DNA- protein adduct by the SPRTN metalloprotease (PubMed:16116421, PubMed:36608669). Can unwind RNA:DNA substrates (PubMed:14983014). Unwinds G-quadruplex DNA; unwinding requires a 5'-single stranded tail (PubMed:18426915, PubMed:20639400). {ECO:0000269|PubMed:11301010, ECO:0000269|PubMed:14983014, ECO:0000269|PubMed:16116421, ECO:0000269|PubMed:16153896, ECO:0000269|PubMed:17596542, ECO:0000269|PubMed:18426915, ECO:0000269|PubMed:20639400, ECO:0000269|PubMed:36608669}.

In 13 of 15 cancers, the evidence for BRIP1 comes mainly from inherited variants

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751familial ovarian cancerfamilial ovarian cancerfamilial ovarian cancer: germline 0.93breast cancerbreast cancerbreast cancer: germline 0.88hereditary breast carcinomahereditary breast carcinomahereditary breast carcinoma: germline 0.95ovarian cancerovarian cancerovarian cancer: somatic 0.43ovarian cancer: germline 0.91hereditary neoplastic syndromehereditary neoplastic syndromehereditary neoplastic syndrome: germline 0.95hereditary breast ovarian cancer syndro…hereditary breast ovarian cancer syndromehereditary breast ovarian cancer syndrome: germline 0.94breast carcinomabreast carcinomabreast carcinoma: somatic 0.46breast carcinoma: germline 0.81ovarian neoplasmovarian neoplasmovarian neoplasm: somatic 0.43ovarian neoplasm: germline 0.82gastric cancergastric cancergastric cancer: germline 0.88breast-ovarian cancer, familial, suscep…breast-ovarian cancer, familial, susceptibility to, 1breast-ovarian cancer, familial, susceptibility to, 1: germline 0.85familial pancreatic carcinomafamilial pancreatic carcinomafamilial pancreatic carcinoma: germline 0.68ovarian carcinomaovarian carcinomaovarian carcinoma: germline 0.53breast neoplasmbreast neoplasmbreast neoplasm: germline 0.60lymphoid neoplasmlymphoid neoplasmlymphoid neoplasm: somatic 0.61head and neck cancerhead and neck cancer

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

PROTAC
Database Ubiquitination, Half-life Data

gnomAD loss of function constraint: o/e 0.735069990158081 (upper bound 0.8776199817657471). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of BRIP1's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of BRIP1's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.